(https://www.cnbc.com/2026/07/21/novo-nordisk-sues-eli-lilly-glp-1-ads.html) over "deceptive" GLP-1 marketing masks diverging financial trajectories rather than a shared accounting risk. Lilly's revenue growth of 45.6% YoY with net income growth of 126.6% YoY reflects pricing power in GLP-1s, while Novo's 33.1% net margin and flat EPS disclosures suggest execution friction despite 47.3B in revenue.

Research these companies